← Back to Search

Glucagon-like peptide-1 receptor agonist

Semaglutide for Obesity (SELECT Trial)

Phase 3

Waitlist Available

Research Sponsored by Novo Nordisk A/S

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 0, year 2

Awards & highlights

SELECT Trial Summary

This trial is testing whether the drug semaglutide can reduce the risk of cardiovascular events (like heart attacks or strokes) in people who are overweight or obese and have already had one such event. People taking part will be randomly assigned to either take semaglutide or a placebo (dummy) drug, and neither they nor the researchers will know who is taking which. The trial will last for 2.5 to 5 years, with participants making up to 25 visits to the study doctor.

Eligible Conditions

Obesity

SELECT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 0, year 2

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 0, year 2

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0, year 2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time to first occurrence of a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, or non-fatal stroke

Secondary outcome measures

Change in EuroQol five dimensions five level (EQ-5D-5L) questionnaire

Change in HbA1c

Change in High sensitivity C-Reactive Protein (hsCRP)

+25 more

Side effects data

From 2020 Phase 4 trial • 104 Patients • NCT04189848

21%

Nausea

12%

Decreased Appetite

100%

80%

60%

40%

20%

Study treatment Arm

Overall Study

SELECT Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: SemaglutideExperimental Treatment1 Intervention

Participants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.

Group II: Placebo (semaglutide)Placebo Group1 Intervention

Participants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Semaglutide

2019

Completed Phase 4

~5160

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Novo Nordisk A/SLead Sponsor

1,513 Previous Clinical Trials

2,397,420 Total Patients Enrolled

141 Trials studying Obesity

114,429 Patients Enrolled for Obesity

Clinical Reporting Anchor and Disclosure (1452)Study DirectorNovo Nordisk A/S

104 Previous Clinical Trials

85,645 Total Patients Enrolled

28 Trials studying Obesity

26,029 Patients Enrolled for Obesity

Clinical Transparency (dept.2834)Study DirectorNovo Nordisk A/S

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many patients are being included in this experiment?

"Unfortunately, this particular trial is no longer seeking participants. However, there are presently 1191 studies actively admitting patients with overweight and 59 studies for Semaglutide recruiting new participants."

Answered by AI

To your knowledge, are there other similar trials currently being conducted?

"Semaglutide has been researched since 2018, with the first clinical trial sponsored by Novo Nordisk A/S. The medication received Phase 4 drug approval after the initial study which included 1387 patients. Presently, there are 59 active studies regarding Semaglutide across 766 cities and 55 countries."

Answered by AI

What health conditions does Semaglutide help to treat?

"Semaglutide is regularly used to help patients manage their weight over the long term. Additionally, it can be employed as a treatment for other issues like obesity-related comorbidities and in conjunction with calorie restriction and exercise."

Answered by AI

What is the potential severity of adverse effects associated with Semaglutide?

"Semaglutide was given a safety score of 3 by our team at Power. This is because it has progressed to Phase 3 in clinical trials, meaning that there is evidence of efficacy and multiple rounds data confirming its safety."

Answered by AI

Can you please provide more context on Semaglutide's impact?

"The clinical trial for semaglutide was first conducted in 2018 at Novo Nordisk Investigational Site. To date, 124 trials have been completed while 59 are still ongoing. The majority of these live studies are based out of Carlinville, Illinois."

Answered by AI

Are patients being sought for this experiment?

"Unfortunately, this particular trial is not recruiting patients at the moment. Although, it was last updated on March 18th, 2022 and was originally posted on October 24th, 2018. However, there are 1250 other trials that are actively enrolling patients."

Answered by AI

Who else is applying?

What state do they live in?

North Carolina

Utah

Texas

Other

How old are they?

18 - 65

What portion of applicants met pre-screening criteria?

Did not meet criteria

Met criteria

How many prior treatments have patients received?

Why did patients apply to this trial?

I’ve been struggling with obesity since 2018 and I’ve tried going to the gym and diets and nothing seems to be working at all for me , my major anxiety and depression play a big role into this too and I will do whatever it takes to lose some weight and get myself healthy.

PatientReceived no prior treatments